Clinical Trials Directory

Trials / Unknown

UnknownNCT03690076

Human Cardiac Mitochondria in Acute Endocarditis and Obesity

Development of the Purification of Human Cardiac Mitochondria, Characterization of These Organelles and Validation of the Model in Acute Endocarditis and Obesity

Status
Unknown
Phase
Study type
Observational
Enrollment
90 (estimated)
Sponsor
University Hospital, Clermont-Ferrand · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Data about human cardiac mitochondria are cruelly lacking in the literature. However, damages of the activity of these organelles are often the source of abnormal cardiac function in several pathologies. The purpose of this study is to develop a model of purified human cardiac mitochondria, to verify the purity of these organelles and to validate the authenticity of their function in acute endocarditis and obesity, two situations known to alter their activity. Animal studies have shown that microbial infection reduced mitochondrial metabolism whereas obesity increases it. The investigator's hypotheses are the following: 1) acute endocarditis, a form of cardiac microbial infection, reduces the function of human cardiac mitochondria; 2) obesity (body mass index \> 30) activates the metabolism of human cardiac mitochondria.

Detailed description

3 groups of patients: * Controls: patients with normal weight (23 \< BMI \< 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis * Endocarditis: patients with normal weight (23 \< BMI \< 27) carriers of endocarditis with surgery indication * Obese: obese patients (BMI \> 30) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis Comparisons studied: * Controls vs. endocarditis * Controls vs. obese patients

Conditions

Interventions

TypeNameDescription
OTHEREndocarditisComparison : Endocarditis vs. control
OTHERObese vs. controlComparisons : Obese vs. control

Timeline

Start date
2018-10-09
Primary completion
2020-04-30
Completion
2020-09-30
First posted
2018-10-01
Last updated
2019-02-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03690076. Inclusion in this directory is not an endorsement.